Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
Achieve Life Sciences will present 52-week cytisinicline efficacy data for cigarette smoking and e-cigarette cessation at CHEST 2026 on October 20 in Phoenix. The data come from the open-label ORCA-OL trial, which enrolled 475 adults from the prior ORCA-2, ORCA-3 and ORCA-V1 studies, treated with 3 mg three times daily for 52 weeks.
Key figures
- Drug Name
- cytisinicline
- Phase Of Trial
- open-label ORCA-OL (Phase 3 follow-on)
- Trial enrollment
- 475
- Treatment duration weeks
- 52
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.